Trial site
Instituto D'Or de Pesquisa e Ensino (IDOR)
São Paulo, São Paulo 04543-000, BrazilNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 24 trials
- Phase 2/32 trials
- Status
- Active, not recruiting10 trials
- Recruiting5 trials
- Completed1 trial
- Withdrawn1 trial
- Lead sponsor
- Janssen Research & Development, LLC8 trials
- Eli Lilly and Company4 trials
- Pfizer2 trials
- Bristol-Myers Squibb1 trial
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1 trial
- and 1 more
Running trials
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Renata Bonadio, Site 0149
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Milena Perez Mak (principal investigator)
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Contact: Eduardo Rego, Site 0103
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Milena Perez Mak (principal investigator)
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error